Fig. 1 · Structure

Documents & Downloads

INCB 3284 dimesylate

Cat. No. A11104 CAS 887401-93-6

HCCR2 antagonist

INCB 3284 dimesylate is a potent, selective hCCR2 antagonist that exhibits potenct antagonism against monocyte chemoattractant molecule binding to hCCR2 and chemotaxis activity.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
MCP-1-hCCR2 IC50 3.7 nM

INCB 3284 dimesylate Research Summary

This section summarizes 4 in vivo studies of INCB 3284 dimesylate from 3 published references.

INCB 3284 dimesylate In Vivo Studies

In male mice with acute liver failure, intraperitoneal INCB 3284 dimesylate pretreatment before AOM significantly delayed neurological decline, increased time to coma, and reduced serum ALT levels compared with AOM-treated mice. In male Sprague–Dawley rats in the PHH group, intraperitoneal INCB 3284 administered before and after IVH produced a pronounced reduction in ventriculomegaly compared with vehicle-treated rats. In male Sprague-Dawley rats subjected to hemorrhagic shock, a single dose of INCB 3284 administered through the left femoral artery transiently reduced fluid resuscitation requirements compared with vehicle-treated animals. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Delayed Neurological Decline in Acute Liver Failure

Animal study · male C57Bl/6 mice; Acute liver failure; n = 4 [1]

In male mice with acute liver failure, intraperitoneal INCB pretreatment before AOM significantly delayed neurological decline and increased time to coma compared with AOM-treated mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Time to coma, in hoursReported result INCB (1 mg/kg/day ip) for 3 days prior to injection of AOM: significantly delay the neurological decline and increase the time taken to reach coma; P <0.05 compared to AOM-treated mice.[1]

Conditions shared by the study groups

Route
ip
Treatment course
for 3 days prior to injection of AOM
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
INCB 3284 dimesylate 1 mg/kg/dayAOM-treated miceINCB (1 mg/kg/day ip) for 3 days prior to injection of AOM: significantly delay the neurological decline and increase the time taken to reach coma; P <0.05 compared to AOM-treated mice.[1]
INCB 3284 dimesylate 1 mg/kg/day
Model: male C57Bl/6 mice; Acute liver failure; n = 4
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: INCB 3284 dimesylate; Compound label in the paper: INCB 3284

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Materials (S5); Methods > Mouse model of hepatic encephalopathy (S7, S9, S10, S12); Results > Inhibition of CCR2 or CCR4 is protective from AOM-induced neurological decline (S70); Figure 3 legend (S97, S103)

Time to coma, in hours: Time to coma, in hours; comparator: AOM-treated mice — Methods > Mouse model of hepatic encephalopathy (S10); Results > Inhibition of CCR2 or CCR4 is protective from AOM-induced neurological decline (S70); Figure 3 legend (S97, S103)

INCB 3284 dimesylate 1 mg/kg/day · Methods > Mouse model of hepatic encephalopathy (S10); Results > Inhibition of CCR2 or CCR4 is protective from AOM-induced neurological decline (S70); Figure 3 legend (S103)

Reduced Ventriculomegaly in PHH Rats

Animal study · Male Sprague‒Dawley rats; PHH group; n = 3 animals per condition [2]

In male Sprague–Dawley rats in the PHH group, intraperitoneal INCB 3284 administered before and after IVH produced a pronounced reduction in ventriculomegaly compared with vehicle-treated rats.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Lateral ventricles volume analysisReported result INCB3284 (1 mg/kg) every 12 h starting 12 h before IVH and continuing until 36 h after IVH: a pronounced reduction in ventriculomegaly.[2]

Conditions shared by the study groups

Route
intraperitoneal injections
Treatment course
every 12 h starting 12 h before IVH and continuing until 36 h after IVH
Vehicle
10% DMSO in corn oil
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
INCB 3284 1 mg/kgvehicle-treated ratsINCB3284 (1 mg/kg) every 12 h starting 12 h before IVH and continuing until 36 h after IVH: a pronounced reduction in ventriculomegaly.[2]
INCB 3284 1 mg/kg
Model: Male Sprague‒Dawley rats; PHH group; n = 3 animals per condition
Methods and source locations

Compound reported in the paper: INCB 3284

The paper names INCB 3284 without stating the salt or form; not verified as the dimesylate form supplied as A11104. No dose conversion or lot validation.

Materials and methods > Animals (S1); Materials and methods > Posthemorrhagic hydrocephalus (PHH) models (S38); Materials and methods > Drug administration (S63, S64); Results > ChP CCL2 or CCR2 deficiencies effectively mitigate macrophage infiltration, reduce ChP inflammation, and ameliorate hydrocephalus in vivo (S218); Figure 7 legend (S316, S318)

Lateral ventricles volume analysis: Lateral ventricles volume analysis; comparator: vehicle-treated rats — Materials and methods > Drug administration (S64); Results > ChP CCL2 or CCR2 deficiencies effectively mitigate macrophage infiltration, reduce ChP inflammation, and ameliorate hydrocephalus in vivo (S218); Figure 7 legend (S318)

INCB 3284 1 mg/kg · Materials and methods > Drug administration (S64); Results > ChP CCL2 or CCR2 deficiencies effectively mitigate macrophage infiltration, reduce ChP inflammation, and ameliorate hydrocephalus in vivo (S218)

Fluid resuscitation requirements after hemorrhagic shock

Animal study · Male Sprague-Dawley rats (300–405 g); n = 6 [3]

In male Sprague-Dawley rats, a single dose of INCB 3284 administered through the left femoral artery transiently reduced fluid resuscitation requirements after hemorrhagic shock compared with vehicle-treated animals.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Fluid resuscitation in mL/kg required to maintain MAP of 60 mmHg or systolic blood pressure (SBP) of 90 mmHg.Reported result Single dose INCB3284 treatment transiently reduces fluid resuscitation requirements after 60 min of hemorrhagic shock.[3]

Conditions shared by the study groups

Route
left femoral artery
Treatment course
at t = 60 min
Vehicle
1mL NS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
INCB 3284 5 μmol/kg1 mL of normal saline (NS) (n = 6)Single dose INCB3284 treatment transiently reduces fluid resuscitation requirements after 60 min of hemorrhagic shock.[3]
INCB 3284 5 μmol/kg
Model: Male Sprague-Dawley rats (300–405 g); n = 6
Methods and source locations

Compound reported in the paper: INCB 3284

The paper names INCB 3284 without stating the salt or form; not verified as the dimesylate form supplied as A11104. No dose conversion or lot validation.

Materials and methods > Hemorrhagic shock models (S4, S9, S18, S20, S21); Fig 2 legend (S46, S50, S52)

Fluid resuscitation in mL/kg required to maintain MAP of 60 mmHg or systolic blood pressure (SBP) of 90 mmHg.: Fluid resuscitation in mL/kg required to maintain MAP of 60 mmHg or systolic blood pressure (SBP) of 90 mmHg.; comparator: 1 mL of normal saline (NS) (n = 6) — Fig 2 legend (S46, S52)

INCB 3284 5 μmol/kg · Materials and methods > Hemorrhagic shock models (S9, S21); Fig 2 legend (S46)

Reduced Serum ALT Levels in Acute Liver Failure

Animal study · male C57Bl/6 mice; Acute liver failure [1]

In male mice with acute liver failure, intraperitoneal INCB pretreatment before AOM significantly reduced serum ALT levels compared with AOM-treated mice alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Serum ALT levelsReported result INCB (1 mg/kg/day ip) for 3 days prior to injection of AOM: a significant reduction in the levels of ALT levels; P <0.05 compared to AOM-treated mice.[1]

Conditions shared by the study groups

Route
ip
Treatment course
for 3 days prior to injection of AOM
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
INCB 3284 dimesylate 1 mg/kg/dayAOM-treated mice aloneINCB (1 mg/kg/day ip) for 3 days prior to injection of AOM: a significant reduction in the levels of ALT levels; P <0.05 compared to AOM-treated mice.[1]
INCB 3284 dimesylate 1 mg/kg/day
Model: male C57Bl/6 mice; Acute liver failure
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: INCB 3284 dimesylate; Compound label in the paper: INCB 3284

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Materials (S5); Methods > Mouse model of hepatic encephalopathy (S7, S9, S10, S12); Results > Inhibition of CCR2 or CCR4 is protective from AOM-induced neurological decline (S71); Figure 3 legend (S97, S98, S100, S104)

Serum ALT levels: Serum ALT levels; comparator: AOM-treated mice alone — Methods > Mouse model of hepatic encephalopathy (S10); Results > Inhibition of CCR2 or CCR4 is protective from AOM-induced neurological decline (S71); Figure 3 legend (S100, S104)

INCB 3284 dimesylate 1 mg/kg/day · Methods > Mouse model of hepatic encephalopathy (S10); Results > Inhibition of CCR2 or CCR4 is protective from AOM-induced neurological decline (S71); Figure 3 legend (S104)

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 887401-93-6
Applications HCCR2 antagonist
Formula C26H31F3N4O4.2CH4O3S
Molecular Weight 712.8
Synonyms INCB3284
SMILES
COC1=NC=C(C=C1)C2(CCC(CC2)N3CC[C@H](C3)NC(=O)CNC(=O)C4=CC(=CC=C4)C(F)(F)F)O.CS(=O)(=O)O.CS(=O)(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

INCB 3284 dimesylate Research References

  1. [1] McMillin M, Frampton G, Thompson M, et al. Neuronal CCL2 is upregulated during hepatic encephalopathy and contributes to microglia activation and neurological decline. J Neuroinflammation (2014). PMID: 25012628 DOI: 10.1186/1742-2094-11-121 Source material
  2. [2] Wang Q, Liu F, Li Y, et al. Choroid plexus CCL2‒CCR2 signaling orchestrates macrophage recruitment and cerebrospinal fluid hypersecretion in hydrocephalus. Acta Pharm Sin B (2024). PMID: 39525574 DOI: 10.1016/j.apsb.2024.06.020 Source material
  3. [3] Weche M, DeSantis AJ, McGee MY, et al. Effects of chemokine (C-C motif) receptor 2 and 3 antagonists in rat models of hemorrhagic shock. PLoS One (2023). PMID: 37071651 DOI: 10.1371/journal.pone.0284472 Source material

Added to your cart

View Cart Checkout
Loading...